Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
about
To BRAF or not to BRAF: is that even a question anymore?Epilepsy related to developmental tumors and malformations of cortical developmentOne hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literatureMAPK pathway activation in pilocytic astrocytomaWill kinase inhibitors make it as glioblastoma drugs?Pathological and molecular advances in pediatric low-grade astrocytomaSomatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samplesBRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.Pediatric brainstem gangliogliomas show BRAF(V600E) mutation in a high percentage of cases.A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors.Pediatric low-grade gliomas: how modern biology reshapes the clinical field.BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications.Declining childhood and adolescent cancer mortalityDiagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumorsGenomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1Desmoplastic infantile ganglioglioma with late presentation. A clinical, radiological and histopathological analysis.Temporal lobe pleomorphic xanthoastrocytoma and acquired BRAF mutation in an adolescent with the constitutional 22q11.2 deletion syndrome.MYB upregulation and genetic aberrations in a subset of pediatric low-grade gliomas.Chromosome band 7q34 deletions resulting in KIAA1549-BRAF and FAM131B-BRAF fusions in pediatric low-grade Gliomas.p16INK4A and p14ARF tumor suppressor pathways are deregulated in malignant rhabdoid tumors.Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-UpCancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing.In search of targeted therapies for childhood cancer.Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapyBRAF Fusion Analysis in Pilocytic Astrocytomas: KIAA1549-BRAF 15-9 Fusions Are More Frequent in the Midline Than Within the CerebellumInterplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomas.MGMT Promoter Methylation and BRAF V600E Mutations Are Helpful Markers to Discriminate Pleomorphic Xanthoastrocytoma from Giant Cell Glioblastoma.Composite pleomorphic xanthoastrocytoma-epithelioid glioneuronal tumor with BRAF V600E mutation - report of three casesPI3K/AKT pathway alterations are associated with clinically aggressive and histologically anaplastic subsets of pilocytic astrocytoma.Epithelioid GBMs show a high percentage of BRAF V600E mutation.Massive dissemination from spinal cord gangliogliomas negative for BRAF V600E: report of two rare adult cases.Anaplastic PXA in adults: case series with clinicopathologic and molecular featuresBRAF alterations in primary glial and glioneuronal neoplasms of the central nervous system with identification of 2 novel KIAA1549:BRAF fusion variants.Molecular profiling of childhood cancer: Biomarkers and novel therapiesExpression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.Molecular markers in pediatric neuro-oncology.Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion.MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2.Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.Biomarker-based prognostic stratification of young adult glioblastoma
P2860
Q26829788-447C05E4-1725-40DF-BFD2-AC830453768BQ26829946-17D84127-9254-4E2C-ACC9-304F02EFA3D4Q26863688-15AEDFA2-61ED-4598-87FA-F381786794CAQ27006028-A8A98D3C-DDD1-4341-99DA-40E2AF9A3A7EQ27012684-9E999056-16AD-49BE-A70B-735703EA8623Q27026123-473C3E15-A993-4A5D-BB8C-61AE23DE36D1Q28070226-8FA1D495-8FE6-4874-B0FE-61D1924993A4Q31002780-29DF8190-5BEB-4210-A1A1-EB23F7CE5881Q33631039-48C724DE-BD8B-446A-90F9-DB7E8A7DF634Q33764533-CD73806F-5155-4250-9CE4-1BA403059D06Q33847771-4C120556-DD82-403B-B87C-578597B7A741Q33867475-297DED70-F238-443F-88AA-B399E929AF8AQ34060045-9E00C68E-8DBA-4686-95BD-165C498241E5Q34166553-BB58745C-30E5-4CD9-A0E3-6B30BA1216CAQ34342166-7E6457B8-836A-455E-A50A-BD88E32C76FDQ34369775-22A12900-6370-433E-B48A-F94B40BDFA1FQ34388261-CAAFE9A6-4DC3-41F3-87B7-7C5CC79F2C4DQ34734398-F7F77E5F-AA54-49C3-AE2C-EB8698D80255Q34810518-DDA600AE-98ED-42D2-B753-93647026AD58Q35133362-454F0581-2C03-40FE-9E40-421E0D6AD0FAQ35449751-45EB5FF2-4204-46D3-A74C-7590E611726FQ35894536-C6D94539-F8A4-47B4-818A-0528C05A4FE5Q35971733-6C6EA8FD-2628-469D-9F08-5D96D642225CQ36001219-8997176C-6896-43AB-8182-480CBC10AA6CQ36009738-549677ED-883A-4B48-89A4-C7EAC8ACB2E3Q36010103-5C259F38-3E35-4F55-84B8-6E5CDE3933BCQ36037961-ED509405-3607-4E03-8000-45AE9DA45164Q36124655-DBC3F7F6-5752-4586-9C4B-D814D24E87C5Q36157714-09FD5EA9-2D1C-41C6-9C05-A3BC148EB2CEQ36175648-FD4B06DC-1AE5-4EB0-978C-11F4ABCE85DAQ36192363-448F815B-DB93-4894-84F5-427D560B5E58Q36197602-9D262566-A37A-4174-8E2A-EACFF51DAB41Q36239628-C6FF6861-8C56-47E9-9E29-F42A70C78D65Q36250783-137E5C52-D314-4454-944F-B07EB39265F0Q36288263-B0508831-D2A0-4CD0-BFC1-CF0A019DD5A2Q36344704-0B11CD7D-37A8-4E4D-A052-D03B9C6DBEF6Q36376520-32D02CA5-C922-4F2C-9D31-399342949BFFQ36500392-D44FF7FF-2FA5-4D80-92DA-4B426DD107DFQ36525778-344A3EB0-0CAF-4D10-A090-D9D925A8E94AQ36782664-7498A99D-D64F-4830-85CA-B399ECB66CFF
P2860
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@ast
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@en
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@nl
type
label
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@ast
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@en
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@nl
prefLabel
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@ast
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@en
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@nl
P2093
P2860
P356
P1433
P1476
Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas.
@en
P2093
Adam C Resnick
Angela J Sievert
Changqing Ma
Jaclyn A Biegel
Marcia S Brose
Margaret J Dougherty
Mariarita Santi
Phillip B Storm
P2860
P304
P356
10.1093/NEUONC/NOQ007
P577
2010-02-14T00:00:00Z